TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve

TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve

Background The Colibri heart valve (CHV) is a pre-mounted, pre-packaged, low-profile, ready-for-use dry TAVR valve with conical cusp design mounted upon a balloon-expandable delivery system encapsulated within within a 14 Fr sheath. Conclusion In the first human cases of the Colibri pre-mounted dry...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B148-B148
Hauptverfasser: Fish, Richard, Paniagua, David
Format: Artikel
Sprache:eng
Schlagworte:
Balloon treatment
Cardiology
Colibri
FDA approval
Feasibility studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page B148
container_issue 18
container_start_page B148
container_title Journal of the American College of Cardiology
container_volume 70
creator Fish, Richard
Paniagua, David
description Background The Colibri heart valve (CHV) is a pre-mounted, pre-packaged, low-profile, ready-for-use dry TAVR valve with conical cusp design mounted upon a balloon-expandable delivery system encapsulated within within a 14 Fr sheath. Conclusion In the first human cases of the Colibri pre-mounted dry valve technology, clinical outcome early and in late survivors showed sustained clinical benefits.
doi_str_mv 10.1016/j.jacc.2017.09.1148
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1957882811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735109717412484</els_id><sourcerecordid>1957882811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1261-da2233490ba8dcda6057acedb526b19f3c6f563a9fae3a64452024e11ca0b11a3</originalsourceid><addsrcrecordid>eNp9kEFPwzAMhSMEEmPwC7hE4kpL3DRtc-CABgOkSSAYXCM3dSFla0faTtq_p9Xgysmy_J79_DF2DiIEAclVFVZobRgJSEOhQ4A4O2ATUCoLpNLpIZuIVKoAhE6P2UnbVkKIJAM9YW45W44avsCO-FPf2WZNvCl590l87nzbBa4OHvo11vy164vd32zWrFzuHb_1u0v-7ClYN33dUbFvNmi_8IMKvrx5f-HvuNrSKTsqcdXS2W-dsrf53XL2ECye7h9nN4vAQpRAUGAUSRlrkWNW2AIToVK0VOQqSnLQpbRJqRKJukSSmMSxikQUE4BFkQOgnLKL_d6Nb757ajtTNb2vh5MGtEqzLMoABpXcq6xv2tZTaTberdHvDAgzMjWVGZmakakR2oxMB9f13kXDA1tH3rTWUT3Ec55sZ4rG_ev_AdWpfY8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1957882811</pqid></control><display><type>article</type><title>TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Fish, Richard ; Paniagua, David</creator><creatorcontrib>Fish, Richard ; Paniagua, David</creatorcontrib><description>Background The Colibri heart valve (CHV) is a pre-mounted, pre-packaged, low-profile, ready-for-use dry TAVR valve with conical cusp design mounted upon a balloon-expandable delivery system encapsulated within within a 14 Fr sheath. Conclusion In the first human cases of the Colibri pre-mounted dry valve technology, clinical outcome early and in late survivors showed sustained clinical benefits.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2017.09.1148</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Balloon treatment ; Cardiology ; Colibri ; FDA approval ; Feasibility studies</subject><ispartof>Journal of the American College of Cardiology, 2017-10, Vol.70 (18), p.B148-B148</ispartof><rights>2017</rights><rights>Copyright Elsevier Limited Oct 31, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0735109717412484$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Fish, Richard</creatorcontrib><creatorcontrib>Paniagua, David</creatorcontrib><title>TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve</title><title>Journal of the American College of Cardiology</title><description>Background The Colibri heart valve (CHV) is a pre-mounted, pre-packaged, low-profile, ready-for-use dry TAVR valve with conical cusp design mounted upon a balloon-expandable delivery system encapsulated within within a 14 Fr sheath. Conclusion In the first human cases of the Colibri pre-mounted dry valve technology, clinical outcome early and in late survivors showed sustained clinical benefits.</description><subject>Balloon treatment</subject><subject>Cardiology</subject><subject>Colibri</subject><subject>FDA approval</subject><subject>Feasibility studies</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kEFPwzAMhSMEEmPwC7hE4kpL3DRtc-CABgOkSSAYXCM3dSFla0faTtq_p9Xgysmy_J79_DF2DiIEAclVFVZobRgJSEOhQ4A4O2ATUCoLpNLpIZuIVKoAhE6P2UnbVkKIJAM9YW45W44avsCO-FPf2WZNvCl590l87nzbBa4OHvo11vy164vd32zWrFzuHb_1u0v-7ClYN33dUbFvNmi_8IMKvrx5f-HvuNrSKTsqcdXS2W-dsrf53XL2ECye7h9nN4vAQpRAUGAUSRlrkWNW2AIToVK0VOQqSnLQpbRJqRKJukSSmMSxikQUE4BFkQOgnLKL_d6Nb757ajtTNb2vh5MGtEqzLMoABpXcq6xv2tZTaTberdHvDAgzMjWVGZmakakR2oxMB9f13kXDA1tH3rTWUT3Ec55sZ4rG_ev_AdWpfY8</recordid><startdate>20171031</startdate><enddate>20171031</enddate><creator>Fish, Richard</creator><creator>Paniagua, David</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20171031</creationdate><title>TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve</title><author>Fish, Richard ; Paniagua, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1261-da2233490ba8dcda6057acedb526b19f3c6f563a9fae3a64452024e11ca0b11a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Balloon treatment</topic><topic>Cardiology</topic><topic>Colibri</topic><topic>FDA approval</topic><topic>Feasibility studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fish, Richard</creatorcontrib><creatorcontrib>Paniagua, David</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fish, Richard</au><au>Paniagua, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2017-10-31</date><risdate>2017</risdate><volume>70</volume><issue>18</issue><spage>B148</spage><epage>B148</epage><pages>B148-B148</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Background The Colibri heart valve (CHV) is a pre-mounted, pre-packaged, low-profile, ready-for-use dry TAVR valve with conical cusp design mounted upon a balloon-expandable delivery system encapsulated within within a 14 Fr sheath. Conclusion In the first human cases of the Colibri pre-mounted dry valve technology, clinical outcome early and in late survivors showed sustained clinical benefits.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jacc.2017.09.1148</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0735-1097
ispartof Journal of the American College of Cardiology, 2017-10, Vol.70 (18), p.B148-B148
issn 0735-1097
1558-3597
language eng
recordid cdi_proquest_journals_1957882811
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Balloon treatment
Cardiology
Colibri
FDA approval
Feasibility studies
title TCT-359 Late Outcome of the First-in-Human Study of the Colibri Dry, Pre-mounted, Pre-packaged TAVR Valve
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A04%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TCT-359%20Late%20Outcome%20of%20the%20First-in-Human%20Study%20of%20the%20Colibri%20Dry,%20Pre-mounted,%20Pre-packaged%20TAVR%20Valve&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Fish,%20Richard&rft.date=2017-10-31&rft.volume=70&rft.issue=18&rft.spage=B148&rft.epage=B148&rft.pages=B148-B148&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2017.09.1148&rft_dat=%3Cproquest_cross%3E1957882811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1957882811&rft_id=info:pmid/&rft_els_id=S0735109717412484&rfr_iscdi=true